Pfizer said Canada’s health regulator has approved its gene therapy to treat a rare inherited blood clotting disorder called haemophilia B, even before the US decision. The approval was based on late-stage studies that showed a single dose of the drug, to be marketed under the brand name Beqvez, was superior to the current standard of care, which involves replacing a blood-clotting protein called factor IX.